RE:Near termUnfortunately the DFU and tympanic ear trial read out are scedule in Q4 2018 if forecast are respected. I don't see this as a catalist in short term.
The main concern now is what will be the source of cash and how much will it cost to fully fund the operations until cash flow positive since Prometic is in a weak cash position (even if there is the line of credit since it is credit) and also in a weak position to negociate a deal.
Most of the time, when there is a financing in a weak position, the SP will go down, driven by the underwritter that sets condition where the price is set base on the closing SP at a choosen day. And they obviously do what it take to drive it down.